LAST CHANCE TO SAVE! New Trends for Life Sciences at PACK EXPO Southeast
Discover all the latest packaging solutions for life sciences products at the all-new PACK EXPO Southeast in Atlanta, GA, March 10-12, 2025
REGISTER ASAP FOR $30!

FDA Has Approved First Cannabis-Derived Drug

Epidiolex from GW Research Ltd. Has been approved for two rare forms of epilepsy. In the FDA’s eyes, cannabidiol (CBD) now has an accepted medical use.

Epidiolex from GW Research Ltd. Has been approved for two rare forms of epilepsy. In the FDA’s eyes, cannabidiol (CBD) now has an accepted medical use.
Epidiolex from GW Research Ltd. Has been approved for two rare forms of epilepsy. In the FDA’s eyes, cannabidiol (CBD) now has an accepted medical use.

Top Takeaways

  • The first cannabidiol-based drug has been approved for two rare and severe forms of epilepsy.

  • FDA will continue to support research on potential medical uses of marijuana-derived products.

  • The DEA has 90 days to reschedule CBD from its current schedule 1 status.


Today, the FDA granted approval of Epidiolex to GW Research Ltd.The cannabidiol (CBD)-based oral solution is intended for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome—two severe forms of epilepsy—in patients two years of age and older.

Today’s approval marks the first FDA-approved drug that contains a purified drug substance derived from marijuana.

LAST CHANCE TO SAVE! New Tech for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
REGISTER ASAP FOR $30!
LAST CHANCE TO SAVE! New Tech for Life Sciences at PACK EXPO Southeast